Abstract Details

Title Treatment Satisfaction and Optimization With Real-World Use of Ubrogepant for the Acute Treatment of Migraine in Combination With an Anti-Calcitonin Gene–Related Peptide Monoclonal Antibody Preventive: Results From the COURAGE Study

Topic Headache

Presentation(s) P10 - Poster Session 10 (8:00 AM-9:00 AM)

Poster/Presentation
Number 15-001

Background Ubrogepant is an oral CGRP receptor antagonist approved for the acute treatment of migraine. However, the real-world treatment effectiveness and satisfaction when used in combination with an anti-CGRP mAb preventive is unknown.

Objective To evaluate real-world treatment satisfaction and acute treatment optimization in participants using ubrogepant in combination with an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) preventive.

Design/Methods This prospective, observational study evaluated real-world effectiveness of ubrogepant (50 or 100mg) for the acute treatment of migraine when taken with an anti-CGRP mAb, onabotulinumtoxinA, or both, using data collected via the Migraine Buddy application. Eligible adults reported ≥3 migraine attacks in the last 30 days, had treated ≥3 prior attacks with ubrogepant, and had used an anti-CGRP mAb or onabotulinumtoxinA for migraine prevention. After 30 days of real-world use of ubrogepant, participants reported their overall satisfaction with ubrogepant (7-point scale), and overall acute treatment optimization via the Migraine Treatment Optimization Questionnaire (mTOQ-4), a 4-item questionnaire with frequency-based response options (sum scores 0-8; higher scores corresponding to greater treatment optimization).

Results The analysis included 245 participants with data for at least 1 ubrogepant-treated attack while on an anti-CGRP mAb preventive; 1217 ubrogepant-treated attacks were recorded over the 30 days. The majority of participants were female (89.0%) and the mean (standard deviation [SD]) age was 41.2 (10.8) years. The most commonly reported mAbs were erenumab (44.5%) and galcanezumab (35.1%). After 30 days, 72.7% of participants reported being satisfied, very satisfied, or extremely satisfied with ubrogepant treatment when used in combination with an anti-CGRP mAb. Mean (SD) mTOQ-4 scores after 30 days of real-world use of ubrogepant with an anti-CGRP mAb was 5.6 (2.4), indicating moderate optimization.

Conclusions Ubrogepant was associated with high levels of treatment satisfaction and patients’ acute treatment was optimized when used in combination with an anti-CGRP mAb.

Authors/Disclosures
Janette Contreras-De Lama PRESENTER	Janette Contreras-De Lama has received personal compensation for serving as an employee of AbbVie. Janette Contreras-De Lama has stock in AbbVie.
Aubrey Adams, PhD	Dr. Manack Adams has received personal compensation for serving as an employee of Abbvie. Dr. Manack Adams has stock in Abbvie.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Francois Cadiou, MBA (Healint)	Mr. Cadiou has received personal compensation for serving as an employee of Healint.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine)	Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. Dr. Lipton has stock in Axon. Dr. Lipton has stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.